Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Division of Biostatistics, Institute of Health and Equity, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Br J Haematol. 2024 Nov;205(5):1830-1834. doi: 10.1111/bjh.19700. Epub 2024 Aug 27.
The Glasgow prognostic score (GPS) and CAR-HEMATOTOX (CAR-HT) score identify multiple myeloma (MM) patients at high risk for immune-mediated toxicity and early mortality with cellular immunotherapy. However, their association with outcomes in patients receiving T-cell redirecting bispecific antibodies (bsAb) is unclear. This multi-centre retrospective study examines the association of baseline GPS and CAR-HT scores with outcomes in 126 MM patients treated with bsAb. Overall, 19% were identified as GPS high risk but did not experience increased toxicity or mortality. Conversely, high-risk CAR-HT patients had a higher incidence of infections and inferior survival, suggesting a need for aggressive infection mitigation strategies.
格拉斯哥预后评分 (GPS) 和 CAR-HEMATOTOX (CAR-HT) 评分可识别出接受细胞免疫疗法的多发性骨髓瘤 (MM) 患者具有免疫介导的毒性和早期死亡的高风险。然而，它们与接受 T 细胞重定向双特异性抗体 (bsAb) 的患者的结局之间的关联尚不清楚。这项多中心回顾性研究探讨了基线 GPS 和 CAR-HT 评分与 126 例接受 bsAb 治疗的 MM 患者结局之间的关联。总体而言，19%的患者被确定为 GPS 高风险，但未出现毒性或死亡率增加的情况。相反，高危 CAR-HT 患者感染发生率更高，生存情况更差，表明需要采取积极的感染缓解策略。
